Eli Lilly remains well-positioned in the obesity treatment market despite early sales of its drug Foundayo underperforming compared to Novo Nordisk's oral Wegovy. The company’s long-term strengths include cost advantages in small molecule manufacturing, potential growth from its new drug Zepbound, and solid gross margin prospects. An updated valuation model places Eli Lilly's stock at about 10% above current levels, supporting a 'Buy' rating. Key risks include continued underperformance of Foundayo, possible Medicare coverage issues, pricing pressures, and execution challenges, but the overall risk/reward outlook is positive ahead of the upcoming Q1 earnings announcement on April 30.
Eli Lilly announced it will acquire psychedelic drugmaker AtaiBeckley for $2.8 billion upfront, gaining access to experimental drugs targeting mental health conditions like treatment-resistant depression. AtaiBeckley's lead drug, a DMT-based nasal sp...
Eli Lilly's stock is projected to grow about 76% over the next three years, reaching around $2,091 per share. This growth is fueled by strong revenue increases from blockbuster drugs like Mounjaro and Zepbound, which contributed $6.7 billion in new r...
